Rein Therapeutics Q1 net loss $5.5M; Phase 2 IPF trial initiated

Rein Therapeutics, Inc.

2025-Q1 EPS reported -$0.25

Net loss $5.5M ($0.25/shr) vs $7.1M ($0.86/shr) year ago; revenue not reported.
Cash $7.4M at Mar 31, plus $5.28M from April warrant/private placement; runway to Sep 2025.
Phase 2 RENEW trial of LTI-03 in IPF initiated; topline interim data expected H1 2026.
Two U.S. patents granted for LTI-03 dry powder formulation (Apr 22, 2025).
R&D expense $3.1M, G&A $2.5M, both down vs prior year on lower legal and LTI-01 costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.